Ampio Pharmaceuticals Inc

ASE:AMPE   3:59:57 PM EDT
1.85
+0.08 (+4.52%)
Products, Regulatory

Ampio Pharmaceuticals Details Early Positive Results For Inhaled Ampion In Covid-19 Respiratory Distress

Published: 03/16/2021 13:24 GMT
Ampio Pharmaceuticals Inc (AMPE) - Ampio Pharmaceuticals Details Early Positive Results for Inhaled Ampion in Covid-19 Respiratory Distress.
Ampio Pharmaceuticals Inc - Ampion Demonstrated Improvement in All-cause Mortality in Covid-19 Patients Compared to Standard of Care.
Ampio Pharmaceuticals Inc - Patients Who Received Ampion Required Less Hospitalization Time.
Ampio Pharmaceuticals Inc - Adverse Events Were Same Between Ampion and Standard of Care.
Ampio Pharmaceuticals Inc - No Drug-related Serious Adverse Events Have Been Reported.
Ampio Pharmaceuticals - Provides Updates on Forthcoming Phase I Clinical Trial Utilizing Inhaled Ampion to Treat "long Hauler" Covid-19 Symptoms.
Ampio Pharmaceuticals Inc - Trial Protocol is Being Finalized, With Commencement of Study Expected by Mid-q2 2021.